Table 4 Pathological details of propensity score–matched patients
EOX group (n = 102) | US group (n = 102) | P | |
|---|---|---|---|
Histology, n (%) | 0.564 | ||
Intestinal | 25 (24.5) | 26 (25.5) | |
Diffuse | 62 (60.8) | 66 (64.7) | |
Mixed/othera | 15 (14.7) | 10 (9.8) | |
Tumour location, n (%) | 0.273 | ||
Lower (antrum, angulus) | 36 (35.3) | 43 (42.2) | |
Middle (body) | 60 (58.8) | 49 (48.0) | |
Upper (fundus, cardia) | 6 (5.9) | 8 (7.8) | |
Otherb | 0 | 2 (2.0) | |
pT category, n (%) | 0.025 | ||
pT0c | 9 (8.8) | 1 (1.0) | |
pT1 | 18 (17.6) | 21 (20.6) | |
pT2 | 22 (21.6) | 17 (16.7) | |
pT3 | 33 (32.4) | 29 (28.4) | |
pT4 | 20 (19.6) | 34 (33.3) | |
Lymph node status, n (%) | 0.008 | ||
Negative | 54 (54.9) | 37 (36.3) | |
Positive | 46 (45.1) | 65 (63.7) | |
cM category, n (%) | 5 (4.9) | 6 (5.9) | 0.757 |
Lymph node harvested, median (IQR) | 21 (14-30) | 24 (17–33) | 0.293 |
Stage, n (%) | 0.030 | ||
0 | 7 (6.9) | 1 (1.0) | |
IA | 13 (12.7) | 15 (14.7) | |
IB | 19 (18.6) | 8 (7.8) | |
IIA | 13 (12.7) | 16 (15.7) | |
IIB | 11 (10.8) | 16 (15.7) | |
IIIA | 16 (15.7) | 9 (8.8) | |
IIIB | 11 (10.8) | 23 (22.5) | |
IIIC | 6 (5.9) | 8 (7.8) | |
IV | 5 (4.9) | 6 (5.9) | |
Metastatic lymph nodes, median (IQR) | 0 (0–4) | 2 (0–6) | 0.004 |
Tumour size (mm), median (IQR | 30.0 (20.0–50.0) | 50 (28.0–85.0) | < 0.001 |
R class, n (%) | 1.000 | ||
R0 | 98 (96.1) | 97 (95.1) | |
R1 | 3 (2.9) | 5 (4.9) | |
R2 | 0 | 1 (1.0) |